Enterprise Value

-1.359B

Cash

3.685B

Avg Qtr Burn

-101.5M

Short % of Float

3.28%

Insider Ownership

0.00%

Institutional Own.

30.56%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Filgotinib Details
Axial spondyloarthritis

Phase 3

Data readout

Filgotinib Details
Crohns disease

Phase 3

Update

GLPG3667 Details
Dermatomyositis

Phase 2

Data readout

GLPG3667 Details
Systemic lupus erythematosus

Phase 2

Data readout

GLPG2737 (CFTR inhibitor) Details
Autosomal Dominant Polycystic Kidney Disease

Phase 2

Data readout

GLPG5101 (CD19 CAR-T) Details
Non-Hodgkin lymphoma

Phase 1/2

Data readout

GLPG5201 (CD19 CAR-T) Details
Small lymphocytic lymphoma , Chronic lymphocytic leukemia

Phase 1/2

Data readout

GLPG5301 BCMA CAR-T Details
Multiple myeloma, High Refractory Multiple Myeloma

Phase 1/2

Data readout

GLPG5101 (CD19 CAR-T) Details
Systemic lupus erythematosus, Autoimmune disease

Phase 1b

Data readout

Ziritaxestat (GLPG1690) Details
Idiopathic pulmonary fibrosis

Failed

Discontinued

GLPG4716 (CHIT1/AMCase inhibitor) Details
Idiopathic pulmonary fibrosis

Failed

Discontinued

GLPG1205 (GPR84 inhibitor) Details
Idiopathic pulmonary fibrosis

Failed

Discontinued

GLPG3970 (SIK2/3 inhibitor) Details
Psoriasis, Rheumatoid arthritis, Ulcerative colitis, Systemic lupus erythematosus

Failed

Discontinued